BLUE PAPER: COVID-19 Quick-Test

In the light of the current global situation, a new inexpensive rapid test for COVID-19 has been conceptually developed and the details are outlined in this document. Given the lack of approved vaccines and anti-viral drugs, the importance of quick diagnoses cannot be understated. Research suggest that antigen material should be readily available in serological samples from the onset until the end of infection. Hence, a direct antigen rapid test, such as the one to be presented here, has the advantage of not being dependent on immune response and the availability of specific immunoglobulin antibodies. Diagnosis should therefore be possible from the first day of symptoms. This is very significant and means that acute diagnosis is theoretically possible.